U.S. markets closed

  • S&P 500

    3,269.96
    -40.15 (-1.21%)
     

  • Dow 30

    26,501.60
    -157.51 (-0.59%)
     

  • Nasdaq

    10,911.59
    -274.00 (-2.45%)
     

  • Russell 2000

    1,538.48
    -23.10 (-1.48%)
     

  • Crude Oil

    35.72
    -0.45 (-1.24%)
     

  • Gold

    1,878.80
    +10.80 (+0.58%)
     

  • Silver

    23.72
    +0.35 (+1.52%)
     

  • EUR/USD

    1.1650
    -0.0029 (-0.24%)
     

  • 10-Yr Bond

    0.8600
    +0.0250 (+2.99%)
     

  • GBP/USD

    1.2951
    +0.0028 (+0.22%)
     

  • USD/JPY

    104.6620
    +0.0520 (+0.05%)
     

  • BTC-USD

    13,554.52
    +255.68 (+1.92%)
     

  • CMC Crypto 200

    264.69
    +1.05 (+0.40%)
     

  • FTSE 100

    5,577.27
    -4.48 (-0.08%)
     

  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

Why Regeneron Is Halting Coronavirus Antibody Cocktail Study Enrollment In Patients With Severe Cases

Shanthi Rexaline
·1 min read

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) faced a setback Friday in a trial evaluating its antibody cocktail REGN-COV2 in hospitalized COVID-19 patients.

What Happened: An independent data monitoring committee recommended that further enrollment of patients requiring high-flow oxygen or mechanical ventilation be placed on hold, citing a potential safety signal and an unfavorable risk-benefit profile at this time, Regeneron said Friday. 

The committee recommended continuing the enrollment of hospitalized patients who require either no or low-flow oxygen, stating that the risk-benefit remains acceptable in these cohorts.

The IDMC has sought modification in the hospitalized patient trial.

It also suggested that the outpatient trial can proceed without modification.

Related Link: The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts

Why It's Important: Regeneron has an emergency use authorization application pending before the FDA for REGN-COV2 in mild-to-moderate coronavirus outpatients at high risk for poor outcomes.

Regeneron's COVID-19 pipeline shot to prominence after the investigational antibody cocktail was administered to President Donald Trump to treat his COVID-19 infection.

Eli Lilly And Co (NYSE: LLY) had to halt its late-stage study of its antibody treatment candidate bamlanivimab in hospitalized severe COVID-19 patients.

REGN Price Action: At last check, Regeneron shares were slipping 2.49% to $541.97. 

Related Link: The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Latest Stories

  • What's the Average 401(k) Balance by Age?

    How much money people have put away for retirement varies, naturally, by their age group. See how your savings stack up.

  • The Newest Electric Car Stock Climbs On First Day Of Trading

    Fisker stock rose in its debut Friday on the New York Stock Exchange as blank-check mergers continue to churn out electric car stocks.

  • The Bottom Is in for These 3 Stocks? Analysts Say ‘Buy’

    Markets are down, but not collapsing. Investors remain worried about the coronavirus, and Tuesday’s election remains up in the air. Uncertainty rules the day, exacerbated by recent market losses. Wall Street, however, expects that the bulls will start running again after next week’s results – who wins will be less important than having a result.In the meantime, market declines and low share prices make for a prime time to buy in – if you judge the bottom correctly. Do that, and the rest is just ‘buy low and sell high.’ And to that end, Wall Street’s analysts have been pointing out stocks that may have hit bottom.Using TipRanks database, we pinpointed three such stocks. Each is down significantly, but each also has a Strong Buy consensus rating and at least 30% upside potential for the coming months.Fury Gold Mines (FURY)Gold – just the precious metal asset – has grown popular during the course of 2020. The coronavirus crisis and investors’ desire for a stable store of value pushed it above $2,000 earlier this year, and one ounce of gold is still selling for over $1,800. For those who haven’t got that kind of resource, however, buying stock in gold miners may be the next best thing.Fury Gold Mines is a small-cap mining company headquartered in Toronto and focused on exploiting the vast resources of the Canadian North. With mines in British Columbia, northern Quebec, and the far-north territory of Nunavut, Fury has large gold reserves in both open pit and underground mines. World gold production dropped by 1% in the last 12 months, giving the first hint that we may be at ‘peak gold,’ and prices will soon increase further.That development would bode well for Fury, which operates at a net loss. The company formed earlier this year, as a restructure of Auryn Resources that involved a merger with Eastmain and the divestment of Peruvian mines. The result is a company that is focused on Canadian development, able to take advantage of Canada’s stable work environment.The stock saw sharp declines recently, when the new FURY ticker started trading, taking Auryn’s place in the market and keeping the older company’s trading history. The drop saw Fury shares shed 67% this month.Covering the stock for Cantor, analyst Matthew O’Keefe sees plenty of upside ahead. The analyst noted, "Based on a combined gold equivalent resource of 3.9Moz, Fury is trading $43/oz versus peers at $60/oz. We expect that, as the new management makes its mark with new drill results (towards the end of 2020 and throughout 2021) and demonstrates advancement of its projects, the stock should move up."But how much up? O’Keefe’s $2.60 price target on FURY suggests a 126% upside potential for the coming year and supports his Buy rating. (To watch O’Keefe’s track record, click here)The Wall Street analyst consensus on Fury is a Strong Buy, based on 4 Buy ratings with no Sells or Holds. The stock is selling for $1.13 and its $3.37 average price target suggests it has room to nearly double in the next 12 months. (See FURY stock analysis on TipRanks)Star Bulk Carries (SBLK)Next up, Star Bulk Carries, is a Greece-based shipping company specializing in the dry bulk ocean carry trade, the backbone of the world’s shipping industry. Star Bulk operates a fleet of 116 carriers, ranging in size from ~50,000 tons to giant Newcastlemax bulk haulers rated over 200,000 tons. The trade disruptions caused by corona were hard on the industry, and SBLK was no exception. The stock is down 47% year-to-date. However, the company’s financial performance this year has been in line with its historical pattern – the first half of a calendar year sees a net loss, while the second half sees net gains. The losses in 1H20 where normal for SBLK’s pattern – and the outlook for Q3 is a return to net profits, with EPS projected at 30 cents.Covering this stock for Deutsche Bank, analyst Amit Mehrotra notes a series of related points: “[We] think the company’s net debt position should improve by about $50M vs. 2Q levels, reflecting cash flow generation in excess of >$40M of debt paydown in 3Q. We also expect the company’s prospective breakeven to reduce to under $11k per day… While we remain frustrated by the lackluster performance of SBLK shares in the context of above-mentioned improving fundamentals...we remain very comfortable that the intrinsic value of SBLK’s equity value is improving in the current environment…” Mehrotra sums up his view of Star Bulk succinctly: “On the whole, we’re encouraged by the fundamental trajectory of the company…” The analyst rates SBLK a Buy, while his $15 price target implies an upside potential of 143% from current levels. (To watch Mehrotra’s track record, click here)With 3 recent Buy reviews, SBLK holds a unanimous Strong Buy rating from the analyst consensus. The stock is currently trading at $6.18 and has an average price target of $12.09, making the one-year upside 96%. (See SBLK stock analysis on TipRanks)Heritage-Crystal Clean (HCCI)Pollution is a problem, no matter what. We all want a clean environment to live in, and we should all care about how modern industrial pollutants are disposed of. Heritage-Crystal Clean inhabits that clean-up niche, providing environmental cleaning services, including vacuum services for street cleaning, light industrial and mechanical parts cleaning technology, and a variety of waste recovery services including recovery and disposal of oil and oil products, antifreezes, and general industrial liquid waste. It’s an important, often overlooked, and vital niche in a modern technological society.After a dip into negative territory in Q2, HCCI reported stronger results for Q3. Revenues gained sequentially from $74 million to $82 million, and EPS swung from a 31-cent loss to an 18-cent gain. Despite the positive results, both earnings and revenues remain depressed compared to the year-ago quarter, and the stock has failed to regain traction after last March’s decline. HCCI is down 49% year-to-date.Roth Capital’s Gerry Sweeney, in his comments on this stock, notes that “Revenue continues to rebound as economic activity improves from COVID shelter in place orders... The highlight in the quarter was a faster than anticipated rebound in margins. While margins are still down from last year’s pre-pandemic level of 25.7%, they are up from 2Q margins of (28.2%). The improvement was driven by higher labor utilization and leverage of assets, lower solvent costs, and the internalization of waste disposal…”Sweeney rates the stock a Buy. His $21 price target indicates confidence in a solid 32% upside for the next year. (To watch Sweeney’s track record, click here.)Over the past three months, three other analysts have thrown the hat in with a view on HCCI. The three additional Buy ratings provide the stock with a Strong Buy consensus rating. With an average price target of $20.75, investors stand to take home a 30% gain, should the target be met over the next 12 months. (See HCCI stock analysis at TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • UPS Says It Lost Tucker Carlson's 'Confidential Documents' Involving Bidens

    Shares of United Parcel Service, Inc. (NYSE: UPS) were unaffected after the company said it was the unnamed company Fox News host Tucker Carlson called out for losing what he said is a politically sensitive package.What Happened: Carlson said during his daily "Tucker Carlson Tonight" show Wednesday that his New York office was in possession of "a collection of confidential documents related to the Biden family."Carlson was in Los Angeles at the time filming an interview with Tony Bobulinski, a former business partner of Hunter Biden, son of Democratic presidential nominee Joe Biden.Carlson asked his office to send over the documents that he described as "authentic" and potentially "damaging" to the Biden campaign. The documents were dropped off at a retail location of a "large national carrier," he said. Carlson didn't elaborate on what the documents are. Related Link: How The 2020 Presidential Election Could Impact Health Care StocksUPS Issues Statement: Carlson didn't name the company during his show. But UPS Corporate Media Relations Director Glenn Zaccara told Business Insider that UPS was the unnamed company."UPS is conducting an urgent investigation into this matter and regrets that the package was damaged," the company told Business Insider."The integrity of our network and the security of our customers' goods are of utmost importance. We will remain in frequent, direct contact with Fox News as we learn more through our investigation."To UPS' credit, Carlson said the company "went far and beyond" but "found nothing.""As of tonight, the company has no idea -- and no working theory, even -- about what happened to this trove of materials, documents that are directly relevant to the presidential campaign just six days from now," the Fox News host said.Photo by Jim.henderson via Wikimedia. See more from Benzinga * Click here for options trades from Benzinga * Molson Coors Stock Chugs Along After Big Q3 Beat * Grocery Prices A Concern As Coronavirus Cases Surge(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Here's how the Biden tax plan would affect each U.S. state

    The ITEP data broke down the impact by state. Population has a major impact on the overall total in tax increases.

  • Disadvantages of Roth IRAs Every Investor Should Know

    Before you open a retirement account, you should know the disadvantages of Roth IRAs. Income limits are one drawback. Learn about the disadvantages of Roth IRAs.

  • Exxon Pressed On Dividend As Huge Writedown Looms While Chevron Earnings Surprise

    Exxon guided investment sharply lower and warned of a massive possible writedown amid questions about its dividend. Chevron reported a surprise profit.

  • Biden’s tax plan: These 5 states would have the highest marginal tax rate

    According to Joe Biden’s tax plan, three states and New York City would see top marginal state and local tax rates of over 60 percent.

  • Jim Cramer On How To Play Stocks On Election Night

    Jim Cramer shared his thoughts on the upcoming election and a potential blue wave.Cramer On The Election: "Let's see if people can fight the blue wave," Cramer said Thursday morning on CNBC. He's concerned about a potential blue wave and that "you have to be."He went on to describe a blue wave as: short and cover when the election night really ends because there's a lot of stocks in a blue wave that would be crimped by a "hijack of the far left."Cramer On A Game Plan: He went on to give a game plan for investors to make "real money.""Short the managed care stocks into a blue wave. The managed care stocks then drop 10%, then you buy the managed care stocks, leading with Centene (NYSE: CNC) and maybe United Health (NYSE: UNH). Pfizer (NYSE: PFE) goes down to $32 ahead of the election, drops to $31.50, people think they made a lot of money, you buy Pfizer," said Cramer."This is what you do, I just gave it to you."Potential Winners Under Biden: Cramer last week discussed his "basket of winners" if presidential candidate Joe Biden were to win the election.He believes investors will go towards the solar industry. Two solar stocks he likes: First Solar (NASDAQ: FSLR) and Tesla (NASDAQ: TSLA).Cramer also thinks infrastructure will be a winner under Biden. Cramer likes these two infrastructure stocks: Caterpillar (NYSE: CAT) and Deere & Company (NYSE: DE).See more from Benzinga * Click here for options trades from Benzinga * 'Halftime Report's' Top Stocks To Watch: AGCO, Keysight And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Amazon Earnings Were Stellar. Here’s Why The Stock Is Falling.

    The e-commerce giant reported sales of $96.1 billion in the third quarter, up 37%, and well ahead of the company’s guidance range of $87 billion to $93 billion.

  • TREASURIES-Yield curve steepest since June as U.S. stocks sell off

    Longer-dated Treasury debt sold off on Friday afternoon, steepening the yield curve to the widest since June, as investors anticipated the deluge of supply that would come from a post-election stimulus package. Investors pulled money out of the U.S. stock market, on track for its worst week since March, on rising COVID cases and election jitters. The benchmark 10-year yield was last up 3.1 basis points to 0.867%.

  • Biden tax proposal might hit wealthy estates with 67% rate

    If Joe Biden wins the November presidential election, the estates of wealthy Americans could be hit with a tax rate as high as 67%, according to a new analysis published by the Tax Foundation.

  • 3 Biotech Stocks in the Hunt for COVID-19 Vaccine; One Analyst Calls Them a ‘Buy’

    Nearly a year into a global pandemic the world is still on the back of its heels. In the face of ever increasing infection rates, world economies have slowed rapidly and unemployment has increased significantly, and now governments are reconsidering shutting down entire countries once again. At the same time, the federal government has failed to pass a second stimulus package to prop up individuals who have lost their jobs and may be facing homelessness, as well as the need to help state and local governments provide a backstop against their own losses.Given this backdrop, there is a lot riding on a potential vaccine and/or cure for COVID-19. There are many approaches that a lengthy list of varying companies are taking to bring their respective product to market.Any company that does successfully bring a product to market that helps in the fight against the virus may see a significant increase in revenues as well as an in-kind increase in profits. B. Riley Securities has highlighted three biotech companies that are approaching the virus from different directions. We ran the trio through TipRanks’ database to see how B. Riley's recent analysis compared to other analysts’ projections.Altimmune Inc. (ALT)Altimmune is a biopharmaceutical company that develops vaccines and immune modulating therapies. Fighting the virus is likely to need both approaches, a vaccine as well as an immune therapy. With this kind of focus, Altimmune’s fortunes changed quickly with the onset of the COVID pandemic.Altimmune produces AdCovid, a single dose, intranasal vaccine to protect against COVID-19. As B. Riley analyst Mayank Mamtani points out, Altimmune’s products “stands out in regards to lung specific IgA and CD8+ T-Cell responses” and further states that “In our view it blocks the virus at the source within the nose and respiratory tract." AdCovid’s preclinical data shows a great deal of promise.ALT stock was trading around $2 per share back in January. Once the company got involved in the fight against COVID-19, the stock jumped up to a high of $33.00 per share, but is now trading at $11; still, this is a move of +450% year-to-date. Given what Altimmune has going for it, and the potential upside, this prompted Mamtani to give Altimmune a Buy rating in his recent analysis. The analyst has a price target of $31, suggesting a potential upside of 182% from current levels. (To watch Mamtani’s track record, click here).As it turns out, there are 4 Buy ratings equating to a Strong Buy on ALT with a low price target of $31 (coming from B. Riley), an average Price target of $49 and a high price target of $80. The average Price Target equates to a potential upside move of 345%. (See ALT stock analysis on TipRanks)Arcturus Therapeutics (ARCT)Arcturus Therapeutics focuses on RNA medicines with a focus on respiratory diseases. COVID, as it may be, is a virus that attacks the respiratory system. Arcturus has a proprietary LNP delivery system that enables a safer, more deliverable method of bioavailable therapy. Regarding this method and Arcturus’ product advancements to this, B. Riley's Mayank Mamtani noted, “Along with the proprietary LNP delivery platform, rapidly biodegradable LUNAR, alongside self-transcribing and replicating mRNA (STARR) technology, implies significant safety and durability advantage."Arcturus has a strong collaboration with Duke University and the Singapore Economic Development Corp to develop LUNAR-Cov19 (ARCT-021) -- a self-replicating mRNA vaccine the might be sufficient to address the Coronavirus outbreak. The potential COVID-19 vaccine is now in a Phase 1/2 trial, and upcoming clinical results are expected in 4Q20. Given the backing and the product development, there appears to be significant potential with this product.ARCT stock started the year at $10 per share but since has jumped to today’s price of $53 this is a 430% year-to-date increase.Considering the potential for the drug making it to market, Mamtani gives ARCT a Buy rating along with an $82 price target. This equates to an upside potential of 52% from current levels.Overall, what does the street have to say about ARCT? There are a total of 6 Buy ratings and all add up to a Strong Buy consensus rating. With an average price target of $75.17, the stock is expected to rise nearly 39% over the next months. (See ARCT stock analysis on TipRanks)Heat Biologics Inc (HTBX)Heat Biologics is a biopharmaceutical that develops immunotherapies. In development is a T-Cell activation platform that is proprietary and is a strong contender in the fight against COVID-19.There are similarities to SARS-Cov-1 from 2003 and today’s COVID-19. As it turns out, and as bad as it sounds, having previously contracted the original SARS-Cov-1 in 2003 would have been a good thing. Patients that recovered from the original SARS-Cov-1 and contracted the current COVID-19, are seeing long-lasting T-Cells memory and are generally asymptomatic or have mild symptoms. Given this, Heat Biologics is using an approach to mimics the original SARS-Cov-1 to provide immunity against COVID-19.Heat Biologics is in collaboration with Waisman Biomanufacturing to manufacture COVID-19 and are preparing to deliver its products to market. As B. Riley's Mamtani points out in his recent analysis, “we view single-dose format of gp96-IgG to serve as complementary to advanced C-19 vaccine candidates in developing combination-based approaches aimed at enhancing T cell immunity."Given the potential of the immunotherapies and T-Cell activation Platform and the partnership with Waisman Biomanufacturing, this prompted Mamtani to place, once again, a Buy rating on Heat Biologics shares. The analyst suggests that if everything goes as planned, HTBX will be a $4 stock in the next 12 months, implying nearly 245% return.As for other Wall Street analysts, there is only one additional rating on HTBX, which is also bullish. The average price target among the two stands at $4.50, which suggests a potential upside of a whopping 288%. (See HTBX stock analysis on TipRanks)To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • ExxonMobil In 'Preservation Mode,' Cramer Says After Q3 Report

    On CNBC Friday morning, Jim Cramer shared his opinions on ExxonMobil's third-quarter earnings report and what's in store for the oil company going forward.Cramer On Exxon Mobil: Jim Cramer pointed to the fall in the price of oil and Exxon Mobil Corporation (NYSE: XOM) struggling."They're in preservation mode."Cramer said the price of oil is not going up, but natural gas might.Related Link: Exxon Mobil's Dividend Yield Hits 10%: What Investors Need To KnowCramer On XTO Acquisition: In 2009, Exxon Mobil paid $41 billion to acquire XTO Energy. Cramer said he was critical of the deal, for which he believes Exxon overpaid. View more earnings on XOMIn the third-quarter report, Exxon announced that it may take a $25-billion to $30-billion impairment charge on its dry gas portfolio. The company plans to complete its assessment in the fourth quarter.When asked what Exxon would be doing with that cash if it didn't acquire, Cramer said the company would probably have spent it on buybacks and dividends as it usually does. Cramer On ExxonMobil's Future: As part of the earnings report, Exxon highlighted its progress in reducing emissions.Exxon partnered with Global Thermostat on a joint venture to "bring to scale breakthrough technology that removes carbon dioxide directly from the atmosphere."Cramer said that when "Exxon decides to get out of the oil industry, [there's] not much there."XOM Price Action: Shares of ExxonMobil were down 0.67% at $32.75 at last check Friday. See more from Benzinga * Click here for options trades from Benzinga * How The 2020 Presidential Election Could Impact Energy Stocks * Stock Wars: ExxonMobil Vs. NextEra, A Battle Of Old Vs. New In Energy(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Does CDC Hint Of Cruise Resumption Make Carnival Stock A Buy Right Now? Here's What Earnings, Charts Show

    Ah, "Carnival." The name conjures smiles. And some cruise lines are about to resume trips. So is this a good time or bad time to invest in Carnival?

  • Dow Jones Plunges 500 Points, As Apple Dives On Earnings; Tesla Skids, While Twitter Crashes 20% On Earnings

    The Dow Jones Industrial Average tumbled 400 points, as Apple dived 5% on weak China sales. Twitter plunged 20% on disappointing user growth.

  • Ant Group: Investors pour US$3 trillion into world's largest IPO with frenzied bids in Hong Kong and Shanghai retail offerings

    The largest initial public offering (IPO) in global financial history broke records in Shanghai and Hong Kong, soaking up more than US$3 trillion from retail investors, setting off frenzied bids for the shares of Ant Group.A record 19.05 trillion yuan (US$2.85 trillion) of bids were received from retail investors for Ant's shares on Shanghai's Star Market, exceeding the supply of shares by 870 times. In Hong Kong, 1.55 million retail investors, or about one-fifth of the city's population, poured in HK$1.3 trillion (US$167.7 billion) for the shares when the book closed at noon on Friday, overbidding by 394 times, according to people familiar with the matter.Get the latest insights and analysis from our Global Impact newsletter on the big stories originating in China.The IPO has already mopped up more money than the stock sale by Chinese bottled water producer Nongfu Spring's HK$677.7 billion. The number of mom-and-pop investors in Ant Group will also exceed the record when 970,000 people submitted bids for the shares of the Industrial and Commercial Bank of China (ICBC) in 2006, according to stock exchange data."The offering is so hot that more than 1 million retail investors have sent their subscriptions," said Louis Tse Ming-kwong, managing director of Hong Kong-based brokerage Wealthy Securities. "It is a historic moment for Hong Kong's securities market."Retail investors submitted a record 19.05 trillion yuan (US$2.85 trillion) in subscription money for Ant's share offering on the Star Market, a board of technology stocks in Shanghai. It amounted to 872 times oversubscription, the firm said in a Shanghai exchange filing late on Thursday.Ant Group offered 1.67 billion shares each in Hong Kong and Shanghai to raise about US$34.5 billion, making it the world's biggest IPO. Including a 15 per cent overallotment in each leg, the total size of the IPO will increase to US$39.67 billion.Strong demand from individual investors in Hong Kong will trigger a mechanism where the retail allocation is raised to a maximum of 10 per cent, from the initial 2.5 per cent.Investors are buying the shares as the valuation is deemed cheaper than overseas payment companies, said Hong Kong Securities Association chairman Gordon Tsui. Ant is the operator of Alipay and an affiliate of Alibaba Group Holding which owns this newspaper."Investors believe in the future economic and technological growth of mainland China," Tse of Wealthy Securities said. "There is an increasing number of people using digital payment. Ant may have more upside room to go if it expands Alipay to overseas markets."Ant Group began taking orders from retail investors in Hong Kong from Tuesday. HSBC, Bank of China (Hong Kong), other retail banks and the city's 600-odd brokerages have made available as much as HK$500 billion of margin financing loans to help investors fund their subscription, more than double the capacity for Nongfu Spring's IPO."We have seen record levels of IPO applications and IPO loan uptake for Ant Group," HSBC said in a statement. The lender set aside HK$150 billion of loans for its customers to subscribe to the shares at an interest rate of 0.48 per cent to 0.88 per cent. How retail investors can increase their chances of getting a piece of Ant Group's blockbuster IPO in Hong KongThe frozen IPO liquidity, however, has not driven up local interest rates substantially, with the one-month interbank offered rate or Hibor rising to 0.48 per cent on Thursday from 0.13 per cent a week earlier. The current level is still lower than 2 per cent in March.Part of the reason is the presence of hot money in the system. More than HK$383.51 billion has entered the local financial system since April, according to HKMA statistics, forcing it to intervene more than 85 times to keep the Hong Kong dollar from breaking the stronger end of its trading band.The inflows pushed the aggregate balance, or the amount of cash sloshing in the banking system, to a record HK$457.46 billion on Friday, or more than eight times the level before the HKMA's currency-market intervention.This article originally appeared in the South China Morning Post (SCMP), the most authoritative voice reporting on China and Asia for more than a century. For more SCMP stories, please explore the SCMP app or visit the SCMP's Facebook and Twitter pages. Copyright © 2020 South China Morning Post Publishers Ltd. All rights reserved. Copyright (c) 2020. South China Morning Post Publishers Ltd. All rights reserved.

  • Henry Kravis Says the Market Is Wilder Than at Any Time in His Career

    (Bloomberg) -- Henry Kravis said there’s more turmoil in the markets than any time in his half-century career as investors react to pandemic news.“I’ve been investing for over 50 years, I don’t remember a time when I’ve seen such volatility as we see today,” Kravis, the co-founder of KKR & Co., said Friday on the Bloomberg Invest Talks webcast. “Just look at our markets in the U.S., we’re up one day 300, 400 points and then the next day, for almost no reason, we’re down 400 to 500 points.”While he praised global stimulus efforts for keeping economies from collapse, he said markets remain unnerved by the Covid-19 pandemic, especially on the prospects for a vaccine. “Any news coming out of the pharmaceutical industry on progress with a therapeutic or with a vaccine is changing sympathy in the markets,” he said.Stocks have been whipsawed this year, sinking into the fastest bear market on record in March before staging a rebound not seen in nine decades. The Cboe’s volatility gauge has averaged 33 since the end of February, 14 points higher than the average over the prior 30 years.Wild swings were also a routine feature of the 2008 financial crisis. That year saw 42 days where the S&P 500 moved by more than 3%, compared with 28 days this year since the pandemic started roiling markets.In the midst of such turbulence, New York-based KKR has been among the most active dealmakers. It has invested more than $40 billion across various strategies this year.“When we shut down our offices in the U.S. on about March 12, I was wondering, ‘What are we going to do, how are we going to even keep busy?’” Kravis, 76, said. “As it turned out, we’ve probably had the busiest year and (most) productive year that we’ve had almost ever.”Kravis has been making deals since he founded KKR in 1976 with Bear Stearns & Co. alums Jerome Kohlberg and his cousin George Roberts. Over the years, they’ve built a reputation as hard-charging capitalists and gained fame with transactions including the takeover of RJR Nabisco Inc. in the 1980s.While buying and selling companies still drives Kravis, he said the pandemic has changed his outlook on life and work.“You see so many people in the U.S., in New York City in particular earlier on, become ill and so many of them pass away,” he said. “It makes you think about what’s really important in life and to me, it’s family, my wife without a doubt.”Beyond that, “I probably have become more patient than I was. I’ve always been known to be impatient,” he said. “Probably my empathy levels have gone up, and trying to show more empathy toward everybody that I come into contact with, people at our firm and make sure they are OK.”For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Coronavirus update: U.S. counts more than 90,000 cases in a single day and The Lancet says Trump pandemic response is ‘disastrous’

    The U.S. death toll from the coronavirus illness COVID-19 headed toward 229,000 on Friday and cases edged toward 9 million, with infections climbing in all swing states just days ahead of the presidential election.

  • 5 Stocks to Buy No Matter Who Wins the Election

    Some trends aren’t dependent on who occupies the White House. Investors should look at Abbott Laboratories, Newmont, SBA Communications, Roper Technologies, and Carlisle.